About: The underlying changes and predicting role of peripheral blood inflammatory cells in severe COVID-19 patients: a sentinel?

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: The underlying changes and predicting role of peripheral blood inflammatory cells in severe COVID-19 patients: a sentinel? Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
title	The underlying changes and predicting role of peripheral blood inflammatory cells in severe COVID-19 patients: a sentinel?
Creator	Zhang, Nan Tang, Ying Li, Yang Zheng, Yang Zhang, Dong Li, Y Cao, Jie Cao, J Gao, L Tang, Y Zhang, D Zheng, Y Zhang, N Cui, C-L Cui, Chang-Lei Gao, Lan Huang, Y-Z Huang, Yan-Zhu Lv, Guo-Yue Sun, D-W Sun, Da-Wei Tian, R-H Tian, Run-Hui Wang, D-X Wang, Dong-Xuan Wang, Y-S Wang, Yu-Shi Zan, T Zan, Tao
source	Elsevier; Medline; PMC
abstract	BACKGROUND: The underlying changes of peripheral blood inflammatory cells (PBICs) in COVID-19 patients are little known. Moreover, the risk factors for the underlying changes of PBICs and their predicting role in severe COVID-19 patients remain uncertain. MATERIAL AND METHODS: This retrospective study including two cohorts: the main cohort enrolling 45 patients of severe type serving as study group, and the secondary cohort enrolling 12 patients of no-severe type serving as control group. The PBICs analysis was based on blood routine and lymphocyte subsets. The inflammatory cell levels were compared among patients according to clinical classifications, disease-associated phases, as well as one-month outcomes. RESULTS: Compared with patients of non-severe type, the patients of severe type suffered from significantly decreased counts of lymphocytes, eosinophils, basophils, but increased counts of neutrophils. These PBICs alterations got improved in recovery phase, but persisted or got worse in aggravated phase. Compared with patients in discharged group, the patients in un-discharged/died group suffered from decreased counts of total T lymphocytes, CD4+T lymphocytes, CD8+T lymphocytes, as well as NK cells at 2 weeks after treatment. Clinical classification-critically severe was the independently risk factor for lymphopenia (OR=7.701, 95%CI:1.265-46.893, P=0.027), eosinopenia (OR=5.595, 95%CI:1.008-31.054, P=0.049) and worse one-month outcome (OR=8.984; 95%CI:1.021-79.061, P=0.048). CONCLUSION: Lymphopenia and eosinopenia may serve as predictors of disease severity and disease progression in COVID-19 patients, and enhancing the cellular immunity may contribute to COVID-19 treatment. Thus, PBICs might become a sentinel of COVID-19, and it deserves attention during COVID-19 treatment.
has issue date	2020-05-14(xsd:dateTime)
bibo:doi	10.1016/j.cca.2020.05.027
bibo:pmid	32417210
has license	no-cc
sha1sum (hex)	a65832fca707c9fbadbf3eef04b75e9bab4a27a4
schema:url	https://doi.org/10.1016/j.cca.2020.05.027
resource representing a document's title	The underlying changes and predicting role of peripheral blood inflammatory cells in severe COVID-19 patients: a sentinel?
has PubMed Central identifier	PMC7224669
has PubMed identifier	32417210
schema:publication	Clin Chim Acta
resource representing a document's body	covid:a65832fca707c9fbadbf3eef04b75e9bab4a27a4#body_text
is schema:about of	named entity 'peripheral blood' named entity 'inflammatory response' named entity 'COVID' named entity 'polymorphonuclear neutrophils' named entity 'natural killer (NK) cells' named entity 'enzyme' named entity 'acute respiratory distress syndrome' named entity 'prognostication' named entity 'sputum' named entity 'lymphocytes' named entity 'eosinopenia' named entity 'peripheral blood' named entity 'lymphopenia' named entity 'COVID' named entity 'infection' named entity 'vascular endothelial' named entity 'Mann-Whitney-Wilcoxon' named entity 'COVID' named entity 'NK cells' named entity 'innate immune' named entity 'ARDS' named entity 'respiratory failure' named entity 'CD4+T cells' named entity 'COVID' named entity 'eosinophils' named entity 'clinical characteristics' named entity 'lung tissue' named entity 'angiotensin' named entity 'COVID-19' named entity 'ALI' named entity 'eosinopenia' named entity 'neutrophils' named entity 'lung' named entity 'COVID' named entity 'peptide' named entity 'SARS-CoV' named entity 'infectious disease' named entity 'COVID' named entity 'risk factors' named entity 'peripheral blood' named entity 'March 16, 2020' named entity 'cellular immune response' named entity 'eosinopenia' named entity 'ligand' named entity 'eosinophil' named entity 'macrophages' named entity 'lymphopenia' named entity 'infection' named entity 'Lymphocyte subsets' named entity 'respiratory disease' named entity 'National Health Commission of China' named entity 'WHO' named entity 'older age'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software